In the adults group, there was no significant difference in the rate of COVID-19 mortality (RR: 1.17; 95% CI: 0.30-4.56; P = 0.82) between the patients with psoriasis receiving IL-17 inhibitors and those receiving non-biologics. Here, IL17A is linked to COVID-19.